Intec's innovative flu treatment Xofluza (baloxavir marboxil) reaches major end in Phase 3 clinical trial

Today, Roche's Genetechcompany,(http://
, announced that its innovative flu treatment, Baloxavir marboxil, had reached its main point in the global phase 3 clinicaltrial(http://called MINISTONE-2Good safety in the treatment of influenza patients aged 1-12 years, while significantly reducing flu symptoms (including fever)The efficacy of Xofluza was comparable to that of the active control groupGenenair will publish detailed data on the trial at the(http://of the upcoming MedicalConferenceThe results are expected to extend the use of Xofluza to children with influenzaAbout XofluzaXofluza, developed by Japan's Yannoyi
pharmaceutical(http://and Roche, is a "first-in-class" oral antiviraldrug(http://that can be taken onceIt can treat strains of virus and avian influenza virus (H7N9, H5N1) that are resistant to oseltamivirXofluza's mechanism of action is different from the antiviral therapy availableIt inhibits virus replication by inhibiting cap-dependent nucleic acid endonucleases in influenza virusesThe mechanism of action of existing anti-flu drugs is through the target neuraminidaseXofluza targets the earlier stages of the virus replication cycle than these drugsLast October, theFDA(http://approved Xofluza for treatment of patients over 12 years of age with no complications of acute influenzaThis is the first innovative flu treatment approved in 20 years